Matteo Bertini
University of Ferrara
39 Papers
58 Citations
Matteo Bertini is an academic researcher from University of Ferrara. The author has contributed to research in topics: Medicine & Cardiac resynchronization therapy. The author has an hindex of 9, co-authored 39 publications. Previous affiliations of Matteo Bertini include Anna University.
Chat about Author
Papers
Relation of QRS Duration to Response to Cardiac Resynchronization Therapy
Biagio Sassone,Simona Gambetti,Matteo Bertini,Matteo Beltrami,Giosuè Mascioli,Sabrina Bressan,Giuseppe Fucà,Federico Pacchioni,Mario Pedaci,Federica Michelotti,Maria Letizia Bacchi Reggiani,Luigi Padeletti +11 more
TL;DR: In patients with LBBB undergoing CRT, a marked QRS widening is related to worse echocardiographic responsiveness and lower event free survival rate compared with patients with an intermediateQRS widening.
32
Remote monitoring of implantable devices: Should we continue to ignore it?
TL;DR: RM is safe, highly reliable, cost efficient, allows quick reply to failures, and reduces the number of scheduled visits and the incidence of inappropriate shocks with a positive impact on survival.
32
Current role of echocardiography in cardiac resynchronization therapy
TL;DR: Current evidence about the role of echocardiography before, during, and after the implantation of a CRT device is reviewed.
22
Antibiotic prophylaxis based on individual infective risk stratification in cardiac implantable electronic device: the PRACTICE study.
Michele Malagù,Francesco Vitali,Alessandro Brieda,Paolo Cimaglia,Martina De Raffele,Enea Tazzari,Cristina Musolino,Cristina Balla,Matteo Serenelli,Rosario Cultrera,Claudio Rapezzi,Matteo Bertini +11 more
TL;DR: In this paper, a large cohort of patients undergoing CIED procedure, an antibiotic prophylaxis based on individual stratification of infective risk resulted in similar rate of infection between groups at high and low risk of CIED-related infection.
20
Frequency of "Pocket" Hematoma in Patients Receiving Vitamin K Antagonist and Antiplatelet Therapy at the Time of Pacemaker or Cardioverter Defibrillator Implantation (from the POCKET Study).
Michele Malagù,Filippo Trevisan,Antonella Scalone,Lina Marcantoni,Giuseppe Sammarco,Matteo Bertini +5 more
TL;DR: New anticoagulant and antiplatelet therapy management protocol was associated with a reduced incidence of clinically significant pocket hematomas, thromboembolic events, pocket infections, and lead dislodgements.
20